Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe liver fuel problems in rare citrin deficiency

NCT ID NCT07055269

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the liver processes energy and removes ammonia in people with citrin deficiency, a rare genetic disorder. Researchers will give participants special 'labeled' water, fructose, and ammonium chloride to track liver activity. By comparing 10 patients with 10 healthy volunteers, they hope to uncover key metabolic problems that could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stable isotopes (heavy water, labeled fructose, and labeled ammonium chloride)
What this could lead to
If successful, this study could reveal how citrin deficiency disrupts liver metabolism, pointing toward new ways to monitor or treat the condition.
What could go wrong
This is a small, early-stage observational study with only 20 participants. It aims to understand the disease, not test a treatment, so direct patient benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for AACD patients are: * Subjects with citrin deficiency, confirmed by genetic analysis to carry pathogenic variant(s) in the SLC25A13 gene * Age from 18 years to 65 years inclusive * Male or female * Written informed consent has been given * Understands and is willing, able and likely to comply with study procedures and restrictions Inclusion criteria for healthy subjects are: * Age from 18 years to 65 years inclusive, and not more than five years younger or older than the specified paired participant from the AACD group * Same sex as the specified paired participant from the AACD group * Same ethnicity the specified paired participant from the AACD group * Written informed consent has been given * Understands and is willing, able and likely to comply with study procedures and restrictions Exclusion criteria for AACD patients are: * acute and chronic disease requiring treatment of any kind, other than his/her AACD * females who are pregnant or lactating or attempting to become pregnant * use of any medication which, in the opinion of the investigator, is likely to interfere with liver function Exclusion criteria for healthy subjects are: * carry any pathogenic variant in the SLC25A13 gene * current or recurrent disease that could affect the metabolic function of the liver * acute and chronic disease requiring treatment of any kind * females who are pregnant or lactating or attempting to become pregnant * use of any medication which, in the opinion of the investigator, is likely to interfere with liver function * weight loss ≥10% within 3 months before study screening * daily alcohol consumption of more than 2 standard-sized beer for men and more than 1 standard-sized beer for women, or the equivalent * BMI \> 30 kg/m2 * currently smoking \>1 cigarette daily * liver transplant recipients * type 1 and 2 diabetes * currently on a ketogenic diet * currently taking medium chain triglyceride (MCT) supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Citrin deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adult-onset citrullinemia type 2 citrin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Children's Hospital Zurich

    Zurich, 8008, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.